Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,371 active trials118 approved drugs1,150 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,734 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,407)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05009953 | Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer | terminated | Phase 2 | 17 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers | terminated | Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2024 |
| clinicaltrials |
| NCT03770455 | Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC | terminated | Phase 2 | 8 | Jodi Layton, MDOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02954523 | Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | terminated | Phase 1 / Phase 2 | 10 | Chul KimOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03631641 | Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy | terminated | Phase 2 | 3 | John HaysOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT02949843 | Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations | terminated | Phase 2 | 19 | Wake Forest University Health SciencesOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT04908956 | Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)(STEREO) | terminated | Phase 2 | 6 | ETOP IBCSG Partners FoundationNETWORK | 8 | Jun 28, 2024 | clinicaltrials |
| NCT00330564 | Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow | terminated | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT04402008 | Study of Poziotinib in Japanese Patients With NSCLC | terminated | Phase 1 / Phase 2 | 42 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03690141 | An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer | terminated | Phase 2 | 16 | Effector TherapeuticsINDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT03968419 | This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.(CANOPY-N) | terminated | Phase 2 | 88 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 20, 2024 | clinicaltrials |
| NCT04037462 | Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy | terminated | Phase 1 / Phase 2 | 2 | VA Office of Research and DevelopmentFED | 1 | Jun 14, 2024 | clinicaltrials |
| NCT03095612 | Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 41 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations | terminated | Phase 1 / Phase 2 | 41 | Turning Point Therapeutics, Inc.INDUSTRY | 2 | Jun 13, 2024 | clinicaltrials |
| NCT04927884 | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies | terminated | Phase 1 / Phase 2 | 3 | ImmunityBio, Inc.INDUSTRY | 1 | Jun 12, 2024 | clinicaltrials |
| NCT04541173 | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) | terminated | Phase 2 | 6 | Aiwu Ruth He, MDOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT03840967 | A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma | terminated | Phase 2 | 14 | Shadia Jalal, MDOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT03450018 | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX(SLC-0111-17-01) | terminated | Phase 1 / Phase 2 | 6 | British Columbia Cancer AgencyOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT03562507 | Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma(ERICA) | terminated | Phase 2 | 8 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT04390243 | Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation | terminated | Phase 2 | 6 | Academic and Community Cancer Research UnitedOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02465957 | QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) | terminated | Phase 2 | 7 | ImmunityBio, Inc.INDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT04476797 | Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC(GRECO-1) | terminated | Phase 1 / Phase 2 | 47 | Galera Therapeutics, Inc.INDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT05648006 | First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer | terminated | Phase 2 | 7 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT04211922 | Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib | terminated | Phase 2 | 4 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06377722 | Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer | terminated | Phase 2 | 18 | Fundacion OncosurNETWORK | 1 | Apr 26, 2024 | clinicaltrials |
| NCT01898156 | Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer | terminated | Phase 1 / Phase 2 | 37 | Kyowa Kirin Korea Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04458311 | Abiraterone Acetate in Combination With Tildrakizumab(ACTIon) | terminated | Phase 1 / Phase 2 | 13 | Institute of Cancer Research, United KingdomOTHER | 2 | Apr 25, 2024 | clinicaltrials |
| NCT04808362 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours(MYCure) | terminated | Phase 1 / Phase 2 | 22 | Peptomyc S.L.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02452970 | RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy(EPIC) | terminated | Phase 2 | 4 | EpicentRx, Inc.INDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT05538624 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary | terminated | Phase 1 / Phase 2 | 14 | Avenge Bio, IncINDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT05709821 | IMM60 and Pembrolizumab in Melanoma and NSCLC | terminated | Phase 1 / Phase 2 | 1 | iOx TherapeuticsINDUSTRY | 3 | Apr 24, 2024 | clinicaltrials |
| NCT02954991 | Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer | terminated | Phase 2 | 161 | Mirati Therapeutics Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT04772053 | Molecular Disease Characterization Initiative (MDCI) | terminated | Phase 2 | 6 | GlaxoSmithKlineINDUSTRY | 2 | Apr 19, 2024 | clinicaltrials |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 47 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Apr 18, 2024 | clinicaltrials |
| NCT03396471 | Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary | terminated | Phase 2 | 14 | Hoosier Cancer Research NetworkOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer | terminated | Phase 2 | 9 | University of ArizonaOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT04027946 | LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Apr 16, 2024 | clinicaltrials |
| NCT04925947 | A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors | terminated | Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT02920996 | Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | terminated | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT03472560 | A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) | terminated | Phase 2 | 61 | PfizerINDUSTRY | 8 | Apr 9, 2024 | clinicaltrials |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma(FIDES-03) | terminated | Phase 1 / Phase 2 | 47 | Basilea PharmaceuticaINDUSTRY | 15 | Apr 4, 2024 | clinicaltrials |
| NCT02540330 | A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant(007) | terminated | Phase 2 | 3 | Atossa Therapeutics, Inc.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT05687617 | Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma. | terminated | Phase 2 | 11 | Laval UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT00889733 | Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer(OVHM-01) | terminated | Phase 1 / Phase 2 | 9 | University Health Network, TorontoOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT01962948 | Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 12 | Fox Chase Cancer CenterOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT02782715 | Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 3 | University of Wisconsin, MadisonOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT03602066 | Study Evaluating The Role of ClO2 on Mucositis for Pt. Undergoing Head/Neck Radiotherapy | terminated | Phase 2 | 14 | University of ArizonaOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT02923739 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT04610684 | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases | terminated | Phase 2 | 3 | Jeffrey ClarkeOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT01953926 | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations(SUMMIT) | terminated | Phase 2 | 582 | Puma Biotechnology, Inc.INDUSTRY | 13 | Mar 12, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Jul 11, 2024source: clinicaltrials